Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases

European Neuropsychopharmacology

Volumn 24, Issue 8, 2014, Pages 1309-1323

  Litjens, Ruud P W ^a,b   Brunt, Tibor M ^b   Alderliefste, Gerard Jan ^c   Westerink, Remco H S ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^c General Recreational Drug Consulting Hours Brijder Addiction Care Center   (Netherlands)

Author keywords

Ecstasy; Hallucinogen; HPPD; LSD; MDMA

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 AMINOBUTYRIC ACID; PRESCRIPTION DRUG; PSYCHEDELIC AGENT; SEROTONIN 2A RECEPTOR; SEROTONIN; SEROTONIN RECEPTOR AFFECTING AGENT;

4 AMINOBUTYRIC ACID RELEASE; ANXIETY; ATTENTION DISTURBANCE; COMORBIDITY; DEPERSONALIZATION; DRUG DEPENDENCE; DRUG EXPOSURE; DRUG USE; HALLUCINOGEN PERSISTING PERCEPTION DISORDER; HUMAN; INTERNEURON; NEOCORTEX; NEUROTOXICITY; NONHUMAN; PANIC; PERCEPTION DISORDER; PHARMACODYNAMICS; PRIORITY JOURNAL; RAPHE NUCLEUS; REVIEW; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION; SIGNAL NOISE RATIO; VISUAL SYSTEM; CHEMICALLY INDUCED; METABOLISM; SENSATION DISORDERS;

HALLUCINOGENS; HUMANS; SENSATION DISORDERS; SEROTONIN; SEROTONIN AGENTS;

EID: 84904999475     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.05.008     Document Type: Review

References (99)

1. Abert B., Ilsen P.F. Palinopsia. Optometry 2010, 81:394-404.
2. Abraham H.D. Visual phenomenology of the LSD flashback. Arch. Gen. Psychiatry 1983, 40:884-889.
3. Abraham H.D., Aldridge A.M. Adverse consequences of lysergic acid diethylamide. Addiction 1993, 88:1327-1334.
4. Abraham H.D., Duffy F.H. Stable quantitative EEG difference in post-LSD visual disorder by split-half analysis: evidence for disinhibition. Psychiatry Res. 1996, 67:173-187.
5. Abraham H.D., Duffy F.H. EEG coherence in post-LSD visual hallucinations. Psychiatry Res. 2001, 107:151-163.
6. Abraham H.D., Mamen A. LSD-like panic from risperidone in post-LSD visual disorder. J. Clin. Psychopharmacol. 1996, 16:238-241.
7. Abraham H.D., Wolf E. Visual function in past users of LSD: psychophysical findings. J. Abnorm. Psychol. 1988, 97:443-447.
8. APA, DSM-IV Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 2000, American Psychiatric Association, Washington, DC. 4th ed.
9. Appel P.W., Ellison A.A., Jansky H.K., Oldak R. Barriers to enrollment in drug abuse treatment and suggestions for reducing them: opinions of drug injecting street outreach clients and other system stakeholders. Am. J. Drug Alcohol Abuse 2004, 30:129-153.
10. Asher H. "Trailing" phenomenon - a long-lasting LSD side effect. Am. J. Psychiatry 1971, 127:1233-1234.
11. Baggott M.J., Coyle J.R., Erowid E., Erowid F., Robertson L.C. Abnormal visual experiences in individuals with histories of hallucinogen use: a web-based questionnaire. Drug Alcohol Depend. 2011, 114:61-67.
12. Bandelow B., Zohar J., Hollander E., Kasper S., Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J. Biol. Psychiatry 2002, 3:171-199.
13. Bauernfeind A.L., Dietrich M.S., Blackford J.U., Charboneau E.J., Lillevig J.G., Cannistraci C.J., Woodward N.D., Cao A., Watkins T., Di Iorio C.R., Cascio C., Salomon R.M., Cowan R.L. Human Ecstasy use is associated with increased cortical excitability: an fMRI study. Neuropsychopharmacology 2011, 36:1127-1141.
14. Billock V.A. Neuroscience: patterns from the brain. Nature 2010, 468:630-631.
15. Billock V.A., Tsou B.H. Elementary visual hallucinations and their relationships to neural pattern-forming mechanisms. Psychol. Bull. 2012, 138:744-774.
16. Perception, International 2006, McGraw-Hill, Boston, [Mass.], London. 5th ed. R. Blake, R. Sekuler (Eds.).
17. Bressloff P.C., Cowan J.D., Golubitsky M., Thomas P.J., Wiener M.C. What geometric visual hallucinations tell us about the visual cortex. Neural Comput. 2002, 14:473-491.
18. Brigo F., Storti M., Tezzon F., Manganotti P., Nardone R. Primary visual cortex excitability in migraine: a systematic review with meta-analysis. Neurol. Sci. 2013, 34:819-830.
19. Brindley G.S. Two new properties of foveal after-images and a photochemical hypothesis to explain them. J. Physiol. 1962, 164:168-179.
20. Brunt T.M., Koeter M.W., Niesink R.J., van den Brink W. Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology 2012, 220:751-762.
21. Carhart-Harris R.L., Nutt D.J. User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study. J. Subst. Use 2010, 15:283-300.
22. Chen W.T., Lin Y.Y., Fuh J.L., Hamalainen M.S., Ko Y.C., Wang S.J. Sustained visual cortex hyperexcitability in migraine with persistent visual aura. Brain 2011, 134:2387-2395.
23. Cooper H.A. Hallucinogenic drugs. Lancet 1955, 268:1078-1079.
24. Cornea-Hebert V., Riad M., Wu C., Singh S.K., Descarries L. Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J. Comp. Neurol. 1999, 409:187-209.
25. Cuyas E., Verdejo-Garcia A., Fagundo A.B., Khymenets O., Rodriguez J., Cuenca A., de Sola Llopis S., Langohr K., Pena-Casanova J., Torrens M., Martin-Santos R., Farre M., de la Torre R. The influence of genetic and environmental factors among MDMA users in cognitive performance. PLoS One 2011, 6:e27206.
26. Dasilva M.A., Grieve K.L., Cudeiro J., Rivadulla C. Endocannabinoid CB1 receptors modulate visual output from the thalamus. Psychopharmacology 2012, 219:835-845.
27. Dubois J., VanRullen R. Visual trails: do the doors of perception open periodically. PLoS Biol. 2011, 9:e1001056.
28. Duman R.S., Li N., Liu R.J., Duric V., Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012, 62:35-41.
29. Elliott B., Joyce E., Shorvon S. Delusions, illusions and hallucinations in epilepsy: 2. Complex phenomena and psychosis. Epilepsy Res. 2009, 85:172-186.
30. Elmenhorst D., Kroll T., Matusch A., Bauer A. Sleep deprivation increases cerebral serotonin 2A receptor binding in humans. Sleep 2012, 35:1615-1623.
31. EMCDDA, 2011. Annual report 2011. The State of the Drugs Problem in Europe.
32. Ferneyhough E., Kim M.K., Phelps E.A., Carrasco M. Anxiety modulates the effects of emotion and attention on early vision. Cogn. Emot. 2013, 27:166-176.
33. Franklin J.M., Carrasco G.A. Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling. Synapse 2013, 67:145-159.
34. Gaillard M.C., Borruat F.X. Persisting visual hallucinations and illusions in previously drug-addicted patients. Klin. Monbl. Augenheilkd. 2003, 220:176-178.
35. Gatch M.B., Rutledge M.A., Carbonaro T., Forster M.J. Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats. Psychopharmacology 2009, 204:715-724.
36. Geyer M.A., Vollenweider F.X. Serotonin research: contributions to understanding psychoses. Trends Pharmacol. Sci. 2008, 29:445-453.
37. Glennon R.A., Titeler M., McKenney J.D. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984, 35:2505-2511.
38. Goodwin A.K., Baker L.E. A three-choice discrimination procedure dissociates the discriminative stimulus effects of d-amphetamine and (+/-)-MDMA in rats. Exp. Clin. Psychopharmacol. 2000, 8:415-423.
39. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol. Rev. 2003, 55:463-508.
40. Halpern J.H., Pope H.G. Hallucinogen persisting perception disorder: what do we know after 50 years. Drug Alcohol Depend. 2003, 69:109-119.
41. Hill M.N., Sun J.C., Tse M.T., Gorzalka B.B. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int. J. Neuropsychopharmacol. 2006, 9:277-286.
42. Holsten F. Flashbacks: a personal follow-up. Arch. Psychiatr. Nervenkr. 1976, 222:293-304.
43. Hughes M.S., Lessell S. Trazodone-induced palinopsia. Arch. Ophthalmol. 1990, 108:399-400.
44. Johnson M.W., Sewell R.A., Griffiths R.R. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend. 2012, 123:132-140.
45. Kilpatrick Z.P., Bard Ermentrout G. Hallucinogen persisting perception disorder in neuronal networks with adaptation. J. Comput. Neurosci. 2012, 32:25-53.
46. Kish S.J., Lerch J., Furukawa Y., Tong J., McCluskey T., Wilkins D., Houle S., Meyer J., Mundo E., Wilson A.A., Rusjan P.M., Saint-Cyr J.A., Guttman M., Collins D.L., Shapiro C., Warsh J.J., Boileau I. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain 2010, 133:1779-1797.
47. Kleinman J.E., Gillin J.C., Wyatt R.J. A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophr. Bull. 1977, 3:560-586.
48. Lerner A.G., Gelkopf M., Oyffe I., Finkel B., Katz S., Sigal M., Weizman A. LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study. Int. Clin. Psychopharmacol. 2000, 15:35-37.
49. Lerner A.G., Gelkopf M., Skladman I., Oyffe I., Finkel B., Sigal M., Weizman A. Flashback and hallucinogen persisting perception disorder: clinical aspects and pharmacological treatment approach. Isr. J. Psychiatry Relat. Sci. 2002, 39:92-99.
50. Lerner A.G., Goodman C., Rudinski D., Bleich A. Benign and time-limited visual disturbances (flashbacks) in recent abstinent high-potency heavy cannabis smokers: a case series study. Isr. J. Psychiatry Relat. Sci. 2011, 48:25-29.
51. Liechti M.E., Baumann C., Gamma A., Vollenweider F.X. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000, 22:513-521.
52. Liu G.T., Schatz N.J., Galetta S.L., Volpe N.J., Skobieranda F., Kosmorsky G.S. Persistent positive visual phenomena in migraine. Neurology 1995, 45:664-668.
53. Manford M., Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain 1998, 121:1819-1840.
54. Markel H., Lee A., Holmes R.D., Domino E.F. LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents. J. Pediatr. 1994, 125:817-819.
55. McCambridge J., Winstock A., Hunt N., Mitcheson L. 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. Eur. Addict. Res. 2007, 13:57-64.
56. McCann U.D., Szabo Z., Seckin E., Rosenblatt P., Mathews W.B., Ravert H.T., Dannals R.F., Ricaurte G.A. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 2005, 30:1741-1750.
57. McGlothlin W.H., Arnold D.O. LSD revisited. A ten-year follow-up of medical LSD use. Arch. Gen. Psychiatry 1971, 24:35-49.
58. Mendiguren A., Pineda J. Effect of the CB(1) receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices. Br. J. Pharmacol. 2009, 158:1579-1587.
59. Morehead D.B. Exacerbation of hallucinogen-persisting perception disorder with risperidone. J. Clin. Psychopharmacol. 1997, 17:327-328.
60. Murray E., Bruno R., Brown J. Residual effects of ecstasy (3,4-methylenedioxymethamphetamine) on low level visual processes. Hum. Psychopharmacol. 2012, 27:226-234.
61. Nichols C.D., Sanders-Bush E. A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology 2002, 26:634-642.
62. Nichols D.E. Hallucinogens. Pharmacol. Ther. 2004, 101:131-181.
63. Nutt D., King L.A., Saulsbury W., Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007, 369:1047-1053.
64. Nutt D.J., King L.A., Phillips L.D. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010, 376:1558-1565.
65. Panayiotopoulos C.P. Visual phenomena and headache in occipital epilepsy: a review, a systematic study and differentiation from migraine. Epileptic Disord. 1999, 1:205-216.
66. Paspalas C.D., Papadopoulos G.C. Serotoninergic afferents preferentially innervate distinct subclasses of peptidergic interneurons in the rat visual cortex. Brain Res. 2001, 891:158-167.
67. Passie T., Halpern J.H., Stichtenoth D.O., Emrich H.M., Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci. Ther. 2008, 14:295-314.
68. Passie T., Schneider U., Emrich H.M. Persisting continuous visual perception disorder in a chronic MDMA ('ecstasy') user. Aust. N Z J. Psychiatry 2002, 36:266-267.
69. Passie T., Seifert J., Schneider U., Emrich H.M. The pharmacology of psilocybin. Addict. Biol. 2002, 7:357-364.
70. Peiro A.M., Farre M., Roset P.N., Carbo M., Pujadas M., Torrens M., Cami J., de la Torre R. Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2h apart. Psychopharmacology 2012.
71. Pinto J.G., Hornby K.R., Jones D.G., Murphy K.M. Developmental changes in GABAergic mechanisms in human visual cortex across the lifespan. Front Cell Neurosci. 2010, 4:16.
72. Purvin V.A. Visual disturbance secondary to clomiphene citrate. Arch. Ophthalmol. 1995, 113:482-484.
73. Ramo D.E., Grov C., Delucchi K., Kelly B.C., Parsons J.T. Typology of club drug use among young adults recruited using time-space sampling. Drug Alcohol Depend. 2010, 107:119-127.
74. Reneman L., Endert E., de Bruin K., Lavalaye J., Feenstra M.G., de Wolff F.A., Booij J. The acute and chronic effects of MDMA ('ecstasy') on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 2002, 26:387-396.
75. Rietjens S.J., Hondebrink L., Westerink R.H., Meulenbelt J. Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions. Crit. Rev. Toxicol. 2012, 42:854-876.
76. Ritschel T., Eisemann E. A computational model of afterimages. Comput. Graph. Forum 2012, 31:529-534.
77. Ritsema M.E., Murphy M.A. Palinopsia from posterior visual pathway lesions without visual field defects. J. Neuroophthalmol. 2007, 27:115-117.
78. Roelfsema P.R., Lamme V.A., Spekreijse H. Object-based attention in the primary visual cortex of the macaque monkey. Nature 1998, 395:376-381.
79. Rotter A., Bayerlein K., Hansbauer M., Weiland J., Sperling W., Kornhuber J., Biermann T. CB1 and CB2 receptor expression and promoter methylation in patients with cannabis dependence. Eur. Addict. Res. 2013, 19:13-20.
80. Russell M.B., Olesen J. A nosographic analysis of the migraine aura in a general population. Brain 1996, 119(Pt 2):355-361.
81. Sato H., Hata Y., Tsumoto T. Effects of blocking non-N-methyl-d-aspartate receptors on visual responses of neurons in the cat visual cortex. Neuroscience 1999, 94:697-703.
82. Schankin, C., Maniyar, F., Hoffmann, J., Chou, D., Goadsby, P., 2013. Clinical characterization of 'visual snow' (positive persistent visual disturbance). The European Headache and Migraine Trust International Congress London, UK.
83. Schouw M.L., Gevers S., Caan M.W., Majoie C.B., Booij J., Nederveen A.J., Reneman L. Mapping serotonergic dysfunction in MDMA (ecstasy) users using pharmacological MRI. Eur. Neuropsychopharmacol. 2012, 22:537-545.
84. Self M.W., Kooijmans R.N., Super H., Lamme V.A., Roelfsema P.R. Different glutamate receptors convey feedforward and recurrent processing in macaque V1. Proc. Natl. Acad. Sci. USA 2012, 109:11031-11036.
85. Sierra M., Medford N., Wyatt G., David A.S. Depersonalization disorder and anxiety: a special relationship. Psychiatry Res. 2012, 197:123-127.
86. Simeon D., Kozin D.S., Segal K., Lerch B. Is depersonalization disorder initiated by illicit drug use any different? A survey of 394 adults. J. Clin. Psychiatry 2009, 70:1358-1364.
87. Smart R.G., Bateman K. Unfavourable reactions to LSD: a review and analysis of the available case reports. Can. Med. Assoc. J. 1967, 97:1214-1221.
88. Studerus E., Gamma A., Kometer M., Vollenweider F.X. Prediction of psilocybin response in healthy volunteers. PLoS One 2012, 7:e30800.
89. Teeple R.C., Caplan J.P., Stern T.A. Visual hallucinations: differential diagnosis and treatment. Prim. Care Companion J. Clin. Psychiatry 2009, 11:26-32.
90. Titeler M., Lyon R.A., Glennon R.A. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 1988, 94:213-216.
91. van der Poel, A., Doekhie, J., Verdurmen, J., Wouters, M., Korf, D.J., van Laar, M., 2010. Feestmeter 2008-2009, Trimbos Report. Trimbos Institute, Utrecht.
92. Vollenweider F.X., Gamma A., Liechti M., Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ('ecstasy') in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998, 19:241-251.
93. Watakabe A., Komatsu Y., Sadakane O., Shimegi S., Takahata T., Higo N., Tochitani S., Hashikawa T., Naito T., Osaki H., Sakamoto H., Okamoto M., Ishikawa A., Hara S., Akasaki T., Sato H., Yamamori T. Enriched expression of serotonin 1B and 2A receptor genes in macaque visual cortex and their bidirectional modulatory effects on neuronal responses. Cereb. Cortex 2009, 19:1915-1928.
94. Wilkinson F. Auras and other hallucinations: windows on the visual brain. Prog. Brain Res. 2004, 144:305-320.
95. Winter J.C. Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology 2009, 203:251-263.
96. Yoneda T., Kameyama K., Esumi K., Daimyo Y., Watanabe M., Hata Y. Developmental and visual input-dependent regulation of the CB1 cannabinoid receptor in the mouse visual cortex. PLoS One 2013, 8:e53082.
97. Yu H., Li Q., Wang D., Shi L., Lu G., Sun L., Wang L., Zhu W., Mak Y.T., Wong N., Wang Y., Pan F., Yew D.T. Mapping the central effects of chronic ketamine administration in an adolescent primate model by functional magnetic resonance imaging (fMRI). Neurotoxicology 2012, 33:70-77.
98. Zeki S. Cerebral akinetopsia (visual motion blindness). A review. Brain 1991, 114:811-824.
99. Zilles K., Palomero-Gallagher N., Grefkes C., Scheperjans F., Boy C., Amunts K., Schleicher A. Architectonics of the human cerebral cortex and transmitter receptor fingerprints: reconciling functional neuroanatomy and neurochemistry. Eur. Neuropsychopharmacol. 2002, 12:587-599.